A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2015
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Sargramostim
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms OPTiM
- Sponsors BioVex
- 18 Dec 2015 Results published in an Amgen media release.
- 18 Dec 2015 According to an Amgen media release, the European Commission has approved talimogene laherparepvec (IMLYGIC) for the treamtent of adults with unresectable metastatic melanoma. The approval was based on exploratory subgroup analysis from this trial.
- 16 Nov 2015 Data from this trial will be presented at the 12th International Congress of the Society for Melanoma Research (SMR), as per Amgen media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History